Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$72.00 | Dwdnxx | Wgkxwnlg |
Baxter Earnings: Mildly Exceeds Cautious Expectations on Improving Medical Utilization
Narrow-moat Baxter mildly exceeded expectations in the third quarter, and management largely maintained its 2023 outlook. Our near-term estimates remain roughly in line with these expectations, and we are keeping our $67 fair value estimate intact, well above recent trades.